In an oral presentation at ASGCT, Editas reported that a single dose of EDIT-401 achieved ≥90 percent mean LDL-C reduction across all dose groups in non-human primates (NHPs). ≥90 percent mean LDL-C ...

What was achieved: Researchers corrected SCN1A mutations in mice using prime or base editing, reducing seizures and improving survival. Why it matters: These are the first demonstrations of directly ...

Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical ...

New preclinical data show PBGENE-DMD drove up to a 3x higher dystrophin protein restoration in skeletal muscle and up to 12x higher in respiratory muscle in early-juvenile mice compared to ...

Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the closing of $130.0 million aggregate principal ...

AviadoBio, a pioneering gene therapy company dedicated to developing and delivering potentially transformative medicines for neurodegenerative disorders, today announced positive preclinical data for ...

PerioImplant Innovations of Bloomington, a leading periodontal practice in central Illinois, has launched a new and improved website at  and recently received recognition from professional ...

A Purdue University–affiliated startup working to reshape how staple crops are bred has secured new federal funding aimed at ...

High-tech assisted reproduction is a growing sector for farmers but critics say they jeopardize animal welfare ...

Cibus' herbicide partner for its Rice HT traits, Albaugh, has made substantial positive progress for the herbicide registration process in the U.S. for Rice, however, they are behind initial timeline ...

Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the first quarter ended March 31, 2026. "The Bionano business is healthy, with first ...